| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 6.23B | 5.41B |
| Cost of Revenue | 3.78B | 1.32B |
| Gross Profit | 2.46B | 4.09B |
| Operating Expenses | 2.89B | 2.87B |
| Research and Development | 255.21M | 8.09M |
| Selling, General & Administrative Expenses | 397.22M | 379.08M |
| Selling & Marketing Expenses | 156.51M | 160.82M |
| General & Administrative Expenses | 240.71M | 218.26M |
| Other Expenses | 0 | 254.57M |
| Operating Income | 1.73B | 1.26B |
| Total Other Income/Expenses Net | 149.93M | 147.07M |
| Income Before Tax | 1.88B | 1.4B |
| Income Tax | 508.7M | 365.22M |
| Net Income | 1.33B | 1.06B |
| Basic EPS | 11.92 | 9.45 |
| EPS Diluted | 11.92 | 9.45 |
| Basic Average Shares | 111.83M | 111.82M |
| Diluted Average Shares | 111.88M | 111.82M |
| EBITDA | 2.27B | 1.79B |
Advanced Enzyme Technologies Limited
ADVENZYMES.NS
NSE
276.45INR5.3 (0.33%)
ADVENZYMES.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 10.02B | 9.07B |
| Net Income | 1.33B | 1.06B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | -567.12M | -125.42M |
| Retained Earnings | 10.79B | 10.02B |
| Other Distributions | 205.02M | 824.38M |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 3.07B | 2.89B |
| Annual Depreciation | 352.42M | 350.29M |
| Capital Expenditure | -423.13M | -381.81M |
| Net PPE | 3.14B | 2.92B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 44.42M | 247.9M |
| Goodwill (Previous Year) | 3.21B | 2.96B |
| Goodwill | 3.25B | 3.21B |